APVO Aptevo Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1671584 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY4.0%
TTM EPS YoY100.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-239.1%
ROA-125.9%
ROIC (approx.)-1,145.2%
Asset turnover—
Leverage & solvency
Liabilities / assets71.1%
Debt / equity0.00x
Current ratio1.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3.74M | $3.70M | $3.92M | $3.54M | $4.04M | $3.33M | $3.63M | $3.88M |
| SG&A expense | $2.88M | $2.75M | $2.91M | $2.46M | $3.57M | $2.90M | $2.85M | $2.50M |
| Operating income | -$6.61M | -$6.44M | -$6.84M | -$6.00M | -$7.61M | -$6.23M | -$6.48M | -$6.38M |
| Net income | -$6.55M | -$6.36M | -$6.70M | -$5.81M | -$7.55M | -$6.20M | -$6.41M | -$6.31M |
| EBITDA | -$6.58M | -$6.41M | -$6.80M | -$5.92M | -$7.56M | -$6.18M | -$6.42M | -$6.31M |
| EPS (basic) | -5.19 | -5.31 | -6.41 | — | -40.13 | -151.29 | -1,581.81 | — |
| EPS (diluted) | -5.19 | -5.31 | -6.41 | — | -40.13 | -151.29 | -1,581.81 | — |
| Weighted avg. shares (diluted) | 1.80M | 1.20M | 1.06M | — | 224,947 | 41,008 | 4,051 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.27M | $9.80M | $14.53M | $21.62M | $9.41M | $9.41M | $2.14M | $8.71M |
| Current assets | $9.70M | $10.80M | $15.98M | $23.08M | $22.65M | $11.08M | $3.61M | $10.66M |
| PP&E, net | $353,000 | $236,000 | $268,000 | $303,000 | $384,000 | $432,000 | $482,000 | $543,000 |
| Total assets | $13.36M | $14.52M | $19.90M | $27.19M | $27.00M | $15.62M | $8.34M | $15.59M |
| Current liabilities | $6.46M | $5.19M | $4.76M | $6.05M | $5.61M | $4.89M | $5.39M | $6.21M |
| Total liabilities | $9.50M | $8.48M | $8.29M | $9.81M | $9.60M | $9.10M | $9.81M | $10.84M |
| Shareholders' equity | $3.86M | $6.04M | $11.61M | $17.38M | $17.39M | $6.52M | -$1.47M | $4.75M |
| Shares outstanding | 2.67M | 1.42M | 1.20M | 997,830 | 13.81M | 3.22M | 1.46M | 4,051 |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.69M | -$5.45M | -$7.96M | -$5.24M | -$6.69M | -$7.09M | -$6.58M | -$5.76M |
| Investing cash flow | -$156,000 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $4.32M | $726,000 | $871,000 | $5.79M | $18.34M | $14.36M | $0 | $6.72M |
| Depreciation & amortization | $39,000 | $32,000 | $35,000 | $81,000 | $49,000 | $49,000 | $61,000 | $71,000 |
| Stock-based compensation | $51,000 | $58,000 | $57,000 | $2,000 | $77,000 | -$163,000 | $180,000 | -$72,000 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.